Institute of Pharmaceutical Sciences, Kings College London, 150 Stamford Street, London, SE1 9NH, UK.
Pharmacy Department, Cheyne Wing, Kings College Hospital, Denmark Hill, London, SE5 9RS, UK.
Syst Rev. 2020 Jun 5;9(1):131. doi: 10.1186/s13643-020-01380-z.
Delirium is an acute confusional state, common in critical illness and associated with cognitive decline. There is no effective pharmacotherapy to prevent or treat delirium, although it is scientifically plausible that thiamine could be effective. Thiamine studies in dementia patients are inconclusive. Aside from small numbers, all used oral administration: bioavailability of thiamine is poor; parenteral thiamine bypasses this. In the UK, parenteral thiamine is administered as a compound vitamin B and C solution (Pabrinex®). The aim of this review is to evaluate the effectiveness of parenteral thiamine (alone or in a compound solution) in preventing or treating delirium in critical illness.
We will search for studies in electronic databases (MEDLINE (Pro-Quest), EMBASE, CINAHL, LILACS, CNKI, AMED, and Cochrane CENTRAL), clinical trials registries (WHO International Clinical Trials Registry, ClinicalTrials.gov, and Controlled-trials.com), and grey literature (Google Scholar, conference proceedings, and Index to Theses). We will perform complementary searches of reference lists of included studies, relevant reviews, clinical practice guidelines, or other pertinent documents (e.g. official documents and government reports). We will consider quasi-randomised or randomised controlled trials in critically ill adults. We will include studies that evaluate parenteral thiamine versus standard of care, placebo, or any other non-pharmacological or pharmacological interventions. The primary outcomes will be the delirium core outcome set, including incidence and severity of delirium and cognition. Secondary outcomes are adapted from the ventilation core outcome set: duration of mechanical ventilation, length of stay, and adverse events incidence. Screening, data extraction, and risk of bias assessment will be undertaken independently by two reviewers. If data permits, we will conduct meta-analyses using a random effects model and, where appropriate, sensitivity and subgroup analyses to explore sources of heterogeneity.
This review will provide evidence for the effectiveness of parental thiamine in the prevention or treatment of delirium in critical care. Findings will contribute to establishing the need for a multicentre study of parenteral thiamine in the prevention and treatment of critical care delirium.
PROSPERO CRD42019118808.
谵妄是一种急性意识混乱状态,常见于危重病患者,并与认知功能下降有关。目前尚无有效的药物疗法可预防或治疗谵妄,尽管从科学角度来看,硫胺素可能有效。硫胺素在痴呆患者中的研究尚无定论。除了数量较少之外,所有研究均采用口服给药:硫胺素的生物利用度较差;而肠外硫胺素则可绕过这一过程。在英国,肠外硫胺素作为复合维生素 B 和 C 溶液(Pabrinex®)给药。本综述的目的是评估肠外硫胺素(单独或在复合溶液中)在预防或治疗危重病患者谵妄方面的有效性。
我们将在电子数据库(MEDLINE(Pro-Quest)、EMBASE、CINAHL、LILACS、CNKI、AMED 和 Cochrane CENTRAL)、临床试验注册处(世界卫生组织国际临床试验注册平台、ClinicalTrials.gov 和 Controlled-trials.com)以及灰色文献(Google Scholar、会议记录和论文索引)中搜索研究。我们将对纳入研究的参考文献、相关综述、临床实践指南或其他相关文件(例如官方文件和政府报告)进行补充检索。我们将考虑纳入评估危重病成人肠外硫胺素与标准治疗、安慰剂或任何其他非药物或药物干预措施的随机对照试验。主要结局将是谵妄核心结局集,包括谵妄的发生率和严重程度以及认知功能。次要结局改编自通气核心结局集:机械通气持续时间、住院时间和不良事件发生率。筛选、数据提取和偏倚风险评估将由两名评审员独立进行。如果数据允许,我们将使用随机效应模型进行荟萃分析,并在适当情况下进行敏感性和亚组分析,以探索异质性的来源。
本综述将为肠外硫胺素在危重病患者谵妄的预防或治疗中的有效性提供证据。研究结果将有助于确定在预防和治疗危重病患者谵妄方面开展多中心肠外硫胺素研究的必要性。
PROSPERO CRD42019118808。